• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Pfizer, BioNTech Enter Vax Pact with COVAX

    FDA Approves Janssen’s CABENUVA

    AGC Biologics Appoints Boulder Site GM

    Lilly Completes $1B Acquisition of Prevail

    Top BioPharma Form Accumulus Synergy
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Integrated Continuous Manufacturing ICM

    CONTINUUS Awarded $69.3M DoD Grant

    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    WDSrx Expands Warehouse Network

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Lilly Completes $1B Acquisition of Prevail

    Top BioPharma Form Accumulus Synergy

    Coating Place Wurster Fluid Bed Process Scaling

    AbbVie Licenses ProBioGen’s GlymaxX Technology

    Improving Product Profitability
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Reed-Lane

    Cytovance Biologics

    Aphena Pharma Solutions

    Syngene

    Almac Group
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Emergent BioSolutions

    Reed-Lane

    PCI Pharma Services

    Almac Group

    Cytovance Biologics
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Online Exclusives

    Inhaled Drug Delivery Technology Trends

    The success of new inhaled medicines relies on the correct combination of formulation and device technology.

    Inhaled Drug Delivery Technology Trends
    Related CONTENT
    • Pfizer, BioNTech Enter Vax Pact with COVAX
    • Improving Product Profitability
    • Global Biosciences Co. Selects ValGenesis VLMS
    • The Future of Clinical Trials Series: Part I
    • JS Bio and Etta Biotech Advancing Partnership
    Dr. Sandy Munro, Vice President – Pharmaceutical Development, Vectura11.24.20
    The future commercial success of any new inhaled medicine relies in a large part on the correct combination of formulation and device technology being chosen for its delivery. There are many options, with pressurized metered dose inhalers (pMDIs), dry powder inhalers (DPIs) and nebulization delivery systems being the primary choices for drug developers. Liquid spray inhalers and other, more niche delivery devices, have also been used to good effect in certain instances.
     
    In the interests of speed, there can be a belief that the choice of device should be firmly established right at the beginning of a project, taking the view that this will reduce the requirement to repeat certain pieces of work or the number of modifications that may be required to the system later on. However, in practice, the fastest and most cost-effective route through the development pipeline may actually be to start out using one delivery technology platform, and switch to another commercially-representative platform later on.
     
    Each individual program should be carefully considered, with all the technical characteristics and commercial constraints taken into account before the device is selected for each step on the development pathway, and it is important to bear in mind that there is no one-size-fits-all solution for every project. Generic programs, for example, may have additional constraints in terms of regulators requiring the originator device and formulation to be meticulously reverse engineered, and this may preclude any kind of mid-development switch. A novel drug substance would typically have no such constraints, but they do have a much higher risk profile, so the best approach is usually to try to maximize the probability of success (PoS) using the fastest, lowest cost approach, and then as the asset traverses key milestones, increases PoS and gains in value, to then switch to a more commercially-representative delivery platform. With generic medicines, there is already 100% confidence that the molecule is safe and effective, so it makes much more sense to start the development with the intended formulation and device technology approach.
     
    Each main device platform type (pMDI, DPI or nebulizer) in turn has a myriad of associated formulation and device options that need to be selected, and each of these can affect the performance of the final drug–device combination. A DPI for example, could contain a dry powder formulated via spray drying, or a more traditional micronized drug and lactose blend. A multi-dose device might be selected, or a unit-dose device could be chosen, and in the case of the latter, there is the additional choice of a variety of capsule-based inhaler types or a unit-dose blister device, and there are devices within different air flow resistances and this factor can also influence performance. A further layer of choice comes with the various options for the user interface (the different steps the patient must take to use the device properly), which can have a profound effect on how easy it is for the patient to use their inhaler, and how successfully they receive their medicine to the appropriate region of the lungs. Choosing the right device for the intended patient group can have a major impact on whether the patient chooses to take their medicine at all, so the choices made are hugely influential in determining the ultimate success of a medicine.
     
    Platform options
    It is important that all the possible formulation technologies and delivery devices are considered at the outset. The first decision will be whether the combination of molecular factors, intended patient group or stage of development drives a pMDI, a DPI, or a nebulizer as the most appropriate delivery system.
     
    The pMDI is a familiar, low-cost device that patients generally find straightforward to use. These devices usually give moderate lung deposition but, in contrast to the DPI, the dose range is usually much more limited, and as a reservoir system it is also inherently quite wasteful. Such a device is, therefore, unlikely to be the best option for an expensive biologic drug, or one that requires a high dose (>1 mg).
     
    If a unit-dose blister or capsule DPI is chosen, these can offer good lung deposition plus it can be straightforward to vary the dose in the early stages of development, simply by altering the weight of the formulation fill, or by getting the patient to take multiple individual doses. It is also flexible in terms of the type of formulation it can deliver in high doses with good aerosolization. However, there is little opportunity for a commodity unit-dose capsule device to confer intellectual property protection. A further drawback is the relative complexity of the user interface, but this may be less of an issue in the very early stages of development, where the medicine is only being taken under very controlled conditions.
     
    Multi-unit dose DPIs have really established themselves as the standard of care in the asthma and chronic obstructive pulmonary disease (COPD) market, being portable, simple and quick to use, and typically, carrying a whole month’s therapy in a single device. Their intellectual property protection potential is usually much stronger than for the unit-dose capsule alternatives as well.
     
    While nebulizer devices themselves may cost more than a DPI or a pMDI, (especially if a smart nebulizer is selected), the overall cost of pursuing this approach in the earlier stages of development can still be lower because the formulation process is often simpler and consumes less material. This can be especially true for biologic drugs, so it can still turn out to be the best option even though the delivery time will be longer than for a DPI. Its flexibility in terms of dose range is much greater, and, as previously mentioned, it can be easier to formulate, particularly if the drug has good solubility in water. A smart nebulizer can also provide very high levels of deep lung deposition and highly efficient delivery with minimal waste. This consistency and efficiency in deep lung delivery may help to contribute to a higher likelihood of success in early clinical development.

    Picking the optimal device
    The first consideration when selecting the best device platform and formulation combination will always be what is most compatible with the drug substance for delivery. Whether the drug substance is a small molecule or a biologic may also affect the choice, as will key physical properties such as solubility in water. Practical considerations, such as the likely age range of patients, may also be early considerations; elderly and very young patients are more likely to have dexterity issues, and may find devices with a complex user interface more difficult to use. The pMDI, for example, is superficially very easy for patients to use, but pMDIs can actually be difficult to use well because of the need to carefully coordinate the point of actuation during the inhalation.
     
    It is also important to consider whether the drug is likely to be administered in a hospital setting, or at home, and if it is to be the latter, is the device sufficiently portable to fit in with the patient’s lifestyle? The dosing regimen will also need to be thought about, as well as the target deposition site within the lungs. If the device chosen does not meet the aims of the drug or the lifestyle of the patient, then patient adherence may be negatively affected, both in clinical trials and once the medicine has gained approval.
     
    Cost implications will also need to be judged: while in the early stages of development an expensive device may be less of an issue, but once a product reaches the market, higher device costs may be acceptable in situations involving a niche disease and small patient numbers where lung delivery efficiency of an expensive drug may be paramount. However, for a very high-volume product containing a low-cost API and where moderate drug deposition may be perfectly acceptable for a drug with a very wide therapeutic index, high device costs are less acceptable.
     
    It is also important to understand the long-term strategy for the company developing the medicine, for example, whether the final commercialization of the product is going to be done in-house, or if the company’s plan is to license the medicine to a commercial partner after Phase 1 or Phase 2. If the development strategy is the latter, then cost, speed and maximizing the probability of success are likely to be more important factors in the decision than giving detailed thought to the final commercial presentation. In contrast, with a generic, cost will be a critical consideration from the outset, as will getting into a final commercial presentation equivalent to the originator product, depending on the regulatory filing strategy.
     
    This goes to the heart of the decision-making process. It is important to remember that the delivery device selected in Phase 1 does not have to be the same as the final commercial product. Rather, it needs to be phase appropriate. This will allow the early stages of development, particularly up to proof-of-concept, to progress as rapidly as is feasible, maximizing the probability of success and potentially generating value, before moving on to the development of the more involved and expensive phase of developing the final commercial product, once there is more confidence that the medicine can achieve commercialization.
     
    Of all the considerations, some are more important than others. Clearly, this list is topped by technical considerations: if the drug’s properties are incompatible with a particular formulation or a device, it will be a non-starter. An antibody drug is unlikely to be stable when delivered via jet nebulizer, for example, and a drug given in doses in excess of 1mg would most likely preclude a pMDI.
     
    At the other end of the spectrum, a molecule that is stable in solution and dissolves readily will naturally lend itself to nebulization. This approach also greatly facilitates the provision of multiple dose levels in early stage dose range finding trials because this can be achieved simply by varying volumes of a stock concentration delivered to the patients. Alternatively, this kind of flexibility can also be achieved via a capsule DPI with different fill volumes of a standard dry powder formulation, if this is more appropriate.
     
    The third overriding consideration is whether the drug must be delivered to specific areas of the lungs. In these cases, smart nebulization may well prove to be the obvious choice for the early stages, as this offers the added benefit of providing patient feedback whilst maximizing lung deposition, especially to the smaller airways.
     
    Phase-appropriate choices
    Reduced risk and savings in both time and money can all be achieved if phase-appropriate platforms are selected throughout the development process. Right up to the proof-of-concept stage, it is feasible to change the platform that is used, allowing for speed and value creation in the early stages before a more commercially-appropriate device is selected for later-stage trials.
     
    This concept is now commonplace: the overriding desire is to get a drug into the clinic as fast as possible with a platform that allows dosing flexibility and maximizes deposition, and then focus on the ultimate commercial platform once the concept has been proved. As a result, smart nebulization and commodity capsule DPIs are increasingly being chosen for early stage clinical trials, allowing milestones to be achieved more rapidly. Whilst this initial choice may well remain suitable all the way to market, it might be deemed more commercially-appropriate to transition into a multi-unit-dose DPI instead, particularly if the application is very high volume and where moderate lung deposition may suffice, but also in instances where a multi-unit dose device is considered the standard of care, such as in the case of mild to moderate asthma.
     
    The Covid-19 pandemic has highlighted the need for speed in the early stages of clinical trials. As the coronavirus can cause significant lung damage, there is a desperate need for inhaled therapies that can deliver drugs effectively to the lungs. Many therapies are being trialed, and speed is of the essence, therefore selecting the most appropriate device to allow projects to move into the clinic as soon as possible will allow successful treatments to be more quickly available for those patients who need them.
     
    For early Covid-19 trials, it is likely that high drug deposition will be required in the small airways within the lungs, and it may be that delivering drugs using smart nebulizer technology will provide the best solution to prove the concept. With smart nebulizer devices, there is also reduced potential for there to be fugitive aerosol escaping into the environment because this can be an issue for conventional continuously producing nebulizer systems.
     
    Alternatively, DPI platforms, especially off-the-shelf capsule devices, can also give a rapid route into the clinic if the drug is compatible with this approach. DPIs may have particular value for Covid applications where the drug is being given as prophylaxis or where medicine needs to be stockpiled against future pandemic outbreaks because of the high volume, low cost, generally long shelf-life and ease of use.
     
    Regardless of whether it is a Covid application or not, all of the factors listed above should be considered when determining the best technology and the optimal device at each point on the development pathway. A methodical approach should be taken to analyze the advantages and potential drawbacks of all the options, narrowing down the choices based on the molecule’s properties, the technical requirements, any demands for speed and cost, and with a clear focus on the intended patient population.
     
    Using phase-appropriate technologies may lead to a smart nebulizer or simple capsule device being chosen at the outset, allowing clinical trials to be initiated and proceed in a timely fashion but preserving the flexibility to then either stick with this platform for the remainder of the development or move to a different, more commercially relevant alternative for commercial launch.
     
    Dr. Munro is responsible for Vectura’s new technology development and also for product development programs utilizing Vectura’s smart nebulizer devices. He joined Vectura in 2008 after a 20-year career at GSK, where he progressed to being Global Director of Inhaled Science and Technology. He holds a chemistry degree from the University of Edinburgh, and a PhD in synthetic organic chemistry from the University of East Anglia. He is also an honorary life member of the Aerosol Society.
     
    Related Searches
    • Drug Delivery
    • Drug Development
    Suggested For You
    Pfizer, BioNTech Enter Vax Pact with COVAX  Pfizer, BioNTech Enter Vax Pact with COVAX
    Improving Product Profitability Improving Product Profitability
    Global Biosciences Co. Selects ValGenesis VLMS  Global Biosciences Co. Selects ValGenesis VLMS
    The Future of Clinical Trials Series: Part I The Future of Clinical Trials Series: Part I
    JS Bio and Etta Biotech Advancing Partnership JS Bio and Etta Biotech Advancing Partnership
    Virtual Clinical Trials: The Future of Dermatology Studies Virtual Clinical Trials: The Future of Dermatology Studies
    Bioclinica Partners with Ikcon Pharma Bioclinica Partners with Ikcon Pharma
    Fujifilm, CABIM Get $76M Funding for Mfg. and Innovation Center Fujifilm, CABIM Get $76M Funding for Mfg. and Innovation Center
    RheinCell Therapeutics Achieves GMP Certification RheinCell Therapeutics Achieves GMP Certification
    Almac Sciences Secures Support from Invest NI Almac Sciences Secures Support from Invest NI
    Baxter, Novavax Ink Sterile Manufacturing Agreement Baxter, Novavax Ink Sterile Manufacturing Agreement
    Fujifilm Diosynth Biotechnologies Begins COVID-19 Vax Production Fujifilm Diosynth Biotechnologies Begins COVID-19 Vax Production
    Parexel Appoints Chief Patient Officer Parexel Appoints Chief Patient Officer
    Angelini Pharma Acquires Arvelle Therapeutics for $960M Angelini Pharma Acquires Arvelle Therapeutics for $960M
    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021 The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Related Online Exclusives

    • Analytical Services | Biologics, Proteins, Vaccines | cGMP Manufacture | Drug Development | Fill/Finish
      A New Era of Vaccine and Biologic Drug Development

      A New Era of Vaccine and Biologic Drug Development

      As a result of COVID-19, unprecedented investments in vaccines, diagnostics, and treatments have had a tremendous impact on the Biotechnology industry.
      Kristin Brooks, Managing Editor 01.12.21

    • Clinical Trials | Drug Development | Information Technology
      Advancing Digital Endpoints in Clinical Trials

      Advancing Digital Endpoints in Clinical Trials

      An end-to-end approach to managing wearable devices through clinical development.
      Kristin Brooks, Contract Pharma 12.14.20

    • Bioanalytical Services | cGMP Manufacture | Drug Development | Scale-up/Technology Transfer
      CDMOs: Keeping up with Science & Technology

      CDMOs: Keeping up with Science & Technology

      Enhancing the development of increasingly advanced and complex drug candidates is needed to drive growth in the industry.
      Kristin Brooks, Contract Pharma 11.12.20


    • Clinical Trials | Drug Development | Preclinical Outsourcing
      Accelerating R&D Trends

      Accelerating R&D Trends

      The pandemic has propelled lingering trends into the forefront and increasingly complex molecules and biologics have drug developers outsourcing more.
      Kristin Brooks, Contract Pharma 10.20.20

    • Drug Delivery
      Topical Drugs Poised for Growth

      Topical Drugs Poised for Growth

      The topical drug delivery market is projected to reach $129.8 billion by 2025 from $95.2 billion in 2020, at a CAGR of 6.4%.
      Contract Pharma Staff 10.12.20

    • Drug Delivery
      Drug Delivery Market Report

      Drug Delivery Market Report

      The pharmaceutical drug delivery market was valued at $1,403,082.9 million in 2019 and is projected to reach $2,296,170.9 million by 2027.
      Contract Pharma Staff 10.12.20


    • Biologics, Proteins, Vaccines | Drug Development | Regulatory Affairs
      Expediting a COVID-19 Vaccine: FDA Approval Process

      Expediting a COVID-19 Vaccine: FDA Approval Process

      The pressures of the pandemic are pushing sponsors and FDA to look at both efficacy and speed in developing a vaccine.
      Kristin Brooks, Contract Pharma 08.25.20

    • Drug Development | Information Technology
      Trade Secret Litigation: Vulnerabilities Within Pharma Amid Hacking Efforts

      Trade Secret Litigation: Vulnerabilities Within Pharma Amid Hacking Efforts

      Theft of IP belonging to companies developing biologics and other drugs, including COVID-19 treatments and vaccines, poses a threat to innovation.
      Kristin Brooks, Contract Pharma 08.19.20

    • Drug Delivery | Solid Dosage/Creams/Ointments
      MedPharm Expands U.S. Footprint

      MedPharm Expands U.S. Footprint

      UK topical and transdermal firm invests in $4 million expansion of laboratory facility in Durham, NC.
      Tim Wright, Editor, Contract Pharma 07.23.20


    • Drug Development | Industry News
      Top Companies Report: Biogen

      Top Companies Report: Biogen

      Expands pipeline of disease-modifying therapies for Alzheimer’s and Parkinson’s, adds gene therapies focused on AAV treatments, bolsters biosimilars portfolio.
      Kristin Brooks, Contract Pharma 07.10.20

    • Analytical Services | Biologics, Proteins, Vaccines | Drug Development | Drug Discovery | Laboratory Testing
      A Shifting Drug Development Landscape Amid COVID-19 Crisis

      A Shifting Drug Development Landscape Amid COVID-19 Crisis

      Responding to demand for challenging assays and custom solutions required for complex molecules, biologics, vaccines and other innovative therapies.
      Kristin Brooks, Contract Pharma 06.22.20

    • Drug Development | Information Technology
      Advancing AI Initiatives in R&D

      Advancing AI Initiatives in R&D

      Richard Lee of ACD/Labs discusses the possibilities of using AI in R&D, and what this outlook means for IT leaders at pharmaceutical organizations.
      Kristin Brooks, Contract Pharma 06.11.20


    • Clinical Trials | CRO News | Drug Development | Information Technology | R&D
      CRO Industry Update

      CRO Industry Update

      Serge Bodart of IDDI provides insight on the pharma and biopharma trends impacting CROs, outsourcing in today’s market, and advances in clinical research.
      Kristin Brooks, Contract Pharma 04.27.20

    • Drug Development | R&D
      COVID-19 and the Importance of Combating Antimicrobial Resistance

      COVID-19 and the Importance of Combating Antimicrobial Resistance

      Dr. Frank of Working to Fight AMR discusses the global COVID-19 pandemic and the critical need to address the public health crisis of Antimicrobial Resistance
      Kristin Brooks, Contract Pharma 04.13.20

    • Biologics, Proteins, Vaccines | cGMP Manufacture | Clinical Trials | Drug Development | Scale-up/Technology Transfer
      Rapid Delivery of Medical Countermeasures Amid Pandemic

      Rapid Delivery of Medical Countermeasures Amid Pandemic

      Robert Erwin of iBio discusses the company’s COVID-19 vaccine development efforts and FastPharming manufacturing platform for the rapid delivery of vaccines
      Kristin Brooks, Contract Pharma 04.03.20

    Trending
    • Integrated Continuous Manufacturing ICM
    • AbbVie Licenses ProBioGen’s GlymaxX Technology
    • CONTINUUS Awarded $69.3M DoD Grant
    Breaking News
    • Pfizer, BioNTech Enter Vax Pact with COVAX
    • FDA Approves Janssen’s CABENUVA
    • AGC Biologics Appoints Boulder Site GM
    • Lilly Completes $1B Acquisition of Prevail
    • Top BioPharma Form Accumulus Synergy
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    NIH Study Compares Low-Fat, Plant-based to Low-Carb, Animal-Based Diet
    Gadot Positions Mineral Line for Vegan Market
    Nutritfy India to Launch Global Broadcast Channel Covering Nutrition
    Coatings World

    Latest Breaking News From Coatings World

    LINE-X Launches Dealer Program with International Truck
    PPG Reports Q4, Full-year 2020 Financial Results
    BASF Begins Implementing Ralignment of Global Business Services Unit
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Cretex Companies CEO Steps Down
    Data Show Porex's Medical Device Filtration Materials Protect Against Virus, Bacteria Spread
    Endoscopic Hemostasis Devices Market Valued at $730 Million
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Pfizer, BioNTech Enter Vax Pact with COVAX
    FDA Approves Janssen’s CABENUVA
    AGC Biologics Appoints Boulder Site GM
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Coty Appoints Chief Procurement Officer
    Lageen Tubes Launches Mono-Material PE Tube Solutions
    Jason Jones Loses Battle with Covid-19
    Happi

    Latest Breaking News From Happi

    Carol’s Daughter Adds New Hair Products
    Moroccan Gold Series Launches NuDo Shampoo
    Youbody Debuts Waterless Body Wash
    Ink World

    Latest Breaking News From Ink World

    BOBST Demonstrates Future of Flexible Packaging Production at Virtual Open House
    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    AR Packaging Acquiring Firstan Holdings Ltd
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Gallus planning virtual event for March
    Lemu Group engineers mask-making machine
    Niagara Label upgrades with Nilpeter flexo press
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Freudenberg to Establish Apparel Interlining Competence Centers
    Minet Adds Spunlace Line in Romania
    Lemu Group Engineers Mask-Making Machine
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Cretex Companies CEO Steps Down
    Conformis Enters Development & Supply Agreement with SITES Medical
    Sectra, RSA Biomedical Sign Distribution Agreement for Implant Stability Tool
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Ambiq Wins IoT Semiconductor Company of the Year Award
    Ynvisible Names Michael Robinson CEO, Jani-Mikael Kuusisto SVP Ventures

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login